Trial
NCT03852160
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Janssen-Cilag International NV
Collaborators
—
Condition
Depressive Disorder, Treatment-Resistant
Intervention
Esketamine 28 mg
Why stopped
New design was developed to better fit company strategy, a new study has replaced 5413541TRD3011 study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-27